Glenmark Pharma's Finacea generic infringes Bayer patent, rules a US court
Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent
)
India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a US court ruled on Monday.
The federal court in Wilmington, Delaware said Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent. Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 28 2015 | 4:33 AM IST